Stories in Life Sciences explores the people, technologies, and strategies transforming how ideas move from discovery to real-world impact in healthcare. Presented by MedAxis AI, each episode features candid conversations with founders, scientists, investors, and commercialization leaders from across Biotech, MedTech, Pharma, and Digital Health. From reimagining surgical tools and personalizing neonatal care with AI, to pioneering predictive ophthalmology and developing bioabsorbable implants — we go behind the scenes of the breakthroughs shaping modern medicine. Every conversation bridges commercialization strategy, ethical AI, and human-centered storytelling to uncover how visionary ideas become real-world impact. Whether you're a startup founder, life sciences professional, investor, or simply curious about the future of healthcare innovation, this podcast is your front-row seat to the stories that matter. Subscribe for new epis
Pitch Analysis
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
31%
Guest openness
Selective
Verified email on file
80/100
Required Score
Sign up to generate a grounded pitch for Stories in Life Sciences.
Stories in Life Sciences is a business podcast hosted by Christopher Wilson, with 28 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
About the host
Christopher Wilson hosts Stories in Life Sciences, a business show with 28 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #5
Mustafa Al-Adhami: Diagnosing a UTI and the Right Antibiotic in One Hour | Stories in Life Sciences
Jul 29, 202635 minS2
Most UTIs are treated with a best-guess antibiotic and a two-day wait for the culture. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Mustafa Al-Adhami, Founder and CEO of Astek Diagnostics, to explore how his device confirms the infection and names the right antibiotic in about an hour directly from a patient sample. Mustafa is a refugee turned mechanical engineering PhD and Y Combinator founder who started Astek Diagnostics after his grandfather nearly died from a mistreated UTI. Astek's platform tracks whether bacteria are still metabolizing to deliver a UTI diagnosis and antibiotic recommendation faster than any existing standard of care, with plans to extend the platform to blood testing through a mosquito microfluidic chip. We cover: How Astek's device confirms a UTI and identifies the right antibiotic in about one hour Why roughly half of initial UTI screens come back as false positives The link between untreated UTIs and sepsis and why speed of diagnosis matters How the technology works by tracking whether bacteria are still metabolizing The FDA De Novo pathway and the strategy of starting with neurogenic bladder patients Building a founding team off a single LinkedIn message Extending the platform to blood testing including the mosquito microfluidic chip Fundraising lessons for early-stage life sciences founders Who this is for: founders, operators, and investors in diagnostics, MedTech, and life sciences, and anyone following antimicrobial resistance and the future of rapid infection testing. Chapters: 00:00 Introduction to Mustafa Al-Adhami and his journey 02:06 From refugee to biotech founder 04:45 The story behind Astek Diagnostics 06:17 Current challenges in UTI diagnosis 08:37 How the device detects bacterial respiration 11:09 Integration into hospital workflow 12:29 Regulatory pathway and FDA strategy 15:08 Next steps and funding 16:59 Building a team from scratch 22:54 Advice for early-stage founders 23:44 Long-term vision and platform potential 28:08 The story of the device's name and personal touch Guest: Mustafa Al-Adhami, Founder and CEO, Astek Diagnostics https://astekdx.com https://www.linkedin.com/in/maladhami https://www.linkedin.com/company/astek-diagnostics Host: Christopher Wilson, Founder, MedAxis AI www.medaxisai.org https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai
Andrea McBeth: Building a Microbiome Company Alongside AI with Thaena | Stories in Life Sciences
Jul 7, 202652 minS2
Andrea McBeth left academia, became a naturopath, and made fecal transplant safe and shelf-stable. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Andrea McBeth, Founder and CEO of Thaena, to explore how she built a microbiome company around rigorous science and how her five-person team now uses AI across nearly everything they do. Andrea's path ran from cellular biology and a PhD she left behind to naturopathic medicine and the microbiome. At Thaena, she chose the dietary supplement route over a pharma path, built a donor screening process grounded in microbiome science, and is now focused on the role of postbiotics in the future of the microbiome field. She also brings a thoughtful, ethics-first perspective to running a small science company alongside AI, navigating the valley of death between research and commercialization with a lean team and modern tools. We cover: How Andrea made fecal transplant safe and shelf-stable as a dietary supplement Why she chose the dietary supplement route over the pharma path for Thaena How Thaena screens its donors and what rigorous microbiome health standards look like The role of postbiotics in the future of microbiome science and product development What it looks like to run a five-person science company alongside AI in a thoughtful, ethical way Navigating the valley of death between research and commercialization as a lean biotech The ethics of AI in biotech startups and how Andrea thinks about responsible adoption Who this is for: biotech founders, microbiome researchers, naturopathic practitioners, and life sciences operators interested in the intersection of microbiome science, dietary supplements, and AI-powered startup operations. Chapters: 00:00 Introduction to Thaena and Andrea's Journey 09:10 The Transition from Fecal Transplant to Dietary Supplements 16:14 Donor Screening and the Importance of Microbiome Health 19:29 Navigating the Clinical Landscape and the Valley of Death 24:31 The Role of AI in Accelerating Business and Innovation 26:02 Exploring AI and Obsidian: A Personal Journey 31:16 Ethics in AI: Balancing Innovation and Responsibility 36:18 Navigating Chaos: The Role of AI in Startups 45:40 The Future of AI: Opportunities and Challenges Ahead Guest: Andrea McBeth, Founder and CEO, Thaena https://thaena.com https://www.linkedin.com/in/andrea-mcbeth-nd https://www.linkedin.com/company/thaena-inc Host: Christopher Wilson, Founder, MedAxis AI www.medaxisai.org https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai
Dr. Ruben Lopez: RNA Therapy Formulation at Any Scale | Stories in Life Sciences
Jun 9, 202641 min
RNA therapy formulation is one of the most resource-intensive steps in preclinical development. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Ruben Lopez, Ph.D., Founder of Nanofacile, to explore how his Montreal-based biotech is changing how researchers and biotech companies approach LNP formulation. Ruben holds a Ph.D. from École de technologie supérieure and brings a background in mechatronics, microfluidics, and cancer biology to the problem of RNA delivery. Nanofacile is developing tools that let scientists formulate RNA-loaded lipid nanoparticles faster, at lower cost, and without requiring specialized formulation expertise. The insights behind the platform came from 140+ customer interviews that revealed the real barriers researchers face in this space. We cover: How RNA therapy formulation works and why it creates a bottleneck in preclinical development What Nanofacile Symphony does and how it works in any wet lab with a centrifuge How the AI formulation companion reduces iteration cycles in LNP development What 140+ customer interviews revealed about the real barriers in RNA formulation Building a team organically from shared labs and incubators in Montreal The Montreal biotech ecosystem: District 3, Centech, the Merck Digital Science Studio, and CQDM What the First Access program is and how researchers can get early access to Nanofacile Symphony Who this is for: biotech founders and researchers working on RNA therapies, LNP formulation, targeted drug delivery, or anyone navigating the preclinical development process with limited resources. Guest: Ruben Lopez, Ph.D. Founder, Nanofacile https://www.nanofacile.bio https://ca.linkedin.com/in/ruben-lopez-nanofacile https://ca.linkedin.com/company/nanofacile Host: Christopher Wilson Founder, MedAxis AI www.medaxisai.org https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai
Salim Dhanji: In Vivo CAR Therapy and Accessible Cancer Treatment | Stories in Life Sciences
May 22, 202635 minS2
<p>In vivo CAR therapy delivers cancer-fighting immune cell reprogramming through a simple injection, skipping the external manufacturing process that makes traditional CAR T therapy cost close to half a million dollars per patient. </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Salim Dhanji, PhD, CEO and Co-Founder of ME Therapeutics Holdings Inc. (CSE: METX), to explore how his team is building a platform to bring in vivo CAR therapy to patients who currently have no accessible treatment options.</p><p></p><p>Dr. Salim brings 25+ years as a...
Sirona Dx: Spatial Biology and Single-Cell Analytics in Clinical Programs | Stories in Life Sciences
May 20, 20261h 3mS2
<p>Sirona Dx pioneered the first commercial spatial-omics CRO service in 2018, giving biopharma access to spatial biology and single-cell analytics at the depth and regulatory rigor clinical programs require.</p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Nasry Yassa, PhD, CEO, and Andrew Brown, PhD, Chief Commercial Officer of Sirona Dx, to explore how they built a technical CRO from scratch in Portland, Oregon, and what it takes to bring spatial biology into clinical trial programs.</p><p></p><p>Sirona Dx operates as a GCLP and CLIA...
Every question we get asked before someone starts their trial.
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
What is the difference between Founder Solo and Founder Pro?
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
How do agency tiers work?
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
What is a talent profile?
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Can I switch plans later?
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Do you offer a free trial?
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
What happens if I cancel?
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Is the 20% annual discount automatic?
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
What if I have more than 50 profiles or 20 clients?
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
